Results 101 to 110 of about 7,117 (221)

Acalabrutinib in treatment of patients with chronic lymphocytic leukemia including those at high genetic risk

Acta Haematologica Polonica
Acalabrutinib belongs to a class of Bruton’s tyrosine kinase inhibitors (BTKis) which have become one of the most widely used drugs for the treatment of B-cell malignancies including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL ...
Anna Ewa Wolska-Washer, Tadeusz Robak
doaj   +1 more source

Acalabrutinib [PDF]

Reactions Weekly, 2020
  +4 more sources

Covalent Bruton tyrosine kinase inhibitors across generations: A focus on zanubrutinib [PDF]

Bruton tyrosine kinase (BTK), the primary target of BTK inhibitors, is a key enzyme in the proliferation and survival pathway of neoplastic B-cells. BTK inhibitors are approved in many hematologic malignancies: chronic lymphocytic leukaemia, mantle cell ...
Broccoli, Alessandro, Danesi, Romano, Del Re, Marzia, Zinzani, Pier Luigi   +3 more
core   +1 more source

Evolution of BTK inhibitors [PDF]

The purpose of this clinical review evaluates the evolution of bruton’s tyrosine kinase (BTK) inhibitors in becoming the standard of care in treating chronic lymphocytic leukemia (CLL).
Mathew, Dena
core   +2 more sources

Acalabrutinib

Reactions Weekly, 2022
  +4 more sources

Acalabrutinib in High-Risk Chronic Lymphocytic Leukaemia Naïve Patients: An Italian Multicenter Retrospective Observational Real-Life Experience [PDF]

N/
Autore, Francesco, Fresa, Alberto, Giannarelli, Diana, Innocenti, Idanna, Laurenti, Luca, Mosca, Antonio, Stirparo, Luca, Tedeschi, Alessandra, Tomasso, Annamaria   +8 more
core   +4 more sources

Bruton’s tyrosine kinase inhibition limits endotoxic shock by suppressing IL-6 production by marginal zone B cells in mice

Frontiers in Immunology
Sepsis is a systemic inflammatory response to a severe, life-threatening infection with organ dysfunction. Although there is no effective treatment for this fatal illness, a deeper understanding of the pathophysiological basis of sepsis and its ...
Kazuhiko Kawata, Shinya Hatano, Akemi Baba, Keisuke Imabayashi, Yoshihiro Baba   +4 more
doaj   +1 more source

Treatment Sequencing in Chronic Lymphocytic Leukemia in 2024: Where We Are and Where We Are Headed [PDF]

As treatments with BTK inhibitors and BCL2 inhibitors have replaced the use of chemoimmunotherapy in CLL in both first-line and relapsed patients, it becomes critical to rationalize their use and exploit the full potential of each drug.
Alberto Fresa, Annamaria Tomasso, Antonio Mosca, Francesco Autore, Francesco Iadevaia, Idanna Innocenti, Luca Laurenti, Luca Stirparo, Paolo Ghia   +8 more
core   +2 more sources

Current Therapeutic Sequencing in Chronic Lymphocytic Leukemia

Hematology Reports
The treatment landscape of chronic lymphocytic leukemia (CLL), the most frequent leukemia in adults, is constantly changing. CLL patients can be divided into three risk categories, based on their IGHV mutational status and the occurrence of TP53 ...
Samir Mouhssine, Nawar Maher, Sreekar Kogila, Claudio Cerchione, Giovanni Martinelli, Gianluca Gaidano   +5 more
doaj   +1 more source

Move along, nothing to see here: Btk inhibitors stop platelets sticking to plaques [PDF]

, 2018
Busygina, Bye, Bye, Byrd, Jamasbi, Levade   +5 more
core   +1 more source